Developing Community-Specific Recommendations for First-Line Treatment of Acute Otitis Media: Is High-Dose Amoxicillin Necessary?

PEDIATRICS ◽  
2004 ◽  
Vol 114 (2) ◽  
pp. 342-347 ◽  
Author(s):  
J. Garbutt ◽  
J. W. St. Geme ◽  
A. May ◽  
G. A. Storch ◽  
P. G. Shackelford
Keyword(s):  
Otitis Media ◽  
Acute Otitis Media ◽  
High Dose ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Otitis Media

1994 ◽  
Vol 15 (3) ◽  
pp. 93-93
Keyword(s):  
Otitis Media ◽  
Otitis Media With Effusion ◽  
Pediatric Population ◽  
Acute Otitis Media ◽  
Line Treatment ◽  
First Line ◽  
Tympanostomy Tubes ◽  
First Line Treatment

A reader questioned Dr. Howie's article on otitis media (PIR 1993;14: 320-323) on three counts: 1. His recommendation not to use amoxicillin as first-line treatment for acute otitis media; 2. His discussion of otitis media with perforation; and 3. His recommendation to place tympanostomy tubes in "any youngster who has otitis media with effusion that persists for 6 to 12 weeks." Dr. Howie responds: "I share with you the frustration of the ever-present challenge of otitis media with effusion (OME), whether acute, recurrent acute, or persistent, in the pediatric population that we serve. The `relapsogenic nature' of aminopenicillins (eg, ampicillin and amoxicillin) seems to be part and parcel of the problem.

Refractory eosinophilic fasciitis successfully treated with infliximab: A case report

2021 ◽  
pp. 239719832110043
Author(s):  
Paulina Śmigielska ◽  
Justyna Czarny ◽  
Jacek Kowalski ◽  
Aleksandra Wilkowska ◽  
Roman J. Nowicki
Keyword(s):  
Case Report ◽  
Connective Tissue ◽  
Treatment Failure ◽  
Immunosuppressive Drugs ◽  
Unknown Etiology ◽  
High Dose ◽  
Eosinophilic Fasciitis ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Eosinophilic fasciitis is a rare connective tissue disease of unknown etiology. Therapeutic options include high-dose corticosteroids and other immunosuppressive drugs. We present a typical eosinophilic fasciitis case, which did not respond to first-line treatment, but improved remarkably after infliximab administration. This report demonstrates that in case of initial treatment failure, infliximab might be a relatively safe and effective way of eosinophilic fasciitis management.

Current Treatment Approaches to Newly Diagnosed Multiple Myeloma

2021 ◽  
Vol 44 (12) ◽  
pp. 690-699
Author(s):  
Susanne Ghandili ◽  
Katja C. Weisel ◽  
Carsten Bokemeyer ◽  
Lisa Beatrice Leypoldt
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibody ◽  
Plasma Cell ◽  
Cell Clone ◽  
Unmet Need ◽  
Continuous Treatment ◽  
High Dose ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

<b><i>Background:</i></b> Multiple myeloma is a so far incurable malignant plasma cell disorder. During the past 2 decades, treatment paradigms substantially changed when novel drugs were introduced initially in treatment of relapsed disease and subsequently also in first-line treatment. <b><i>Summary:</i></b> Up to now, first-line treatment differs between patients initially classified as transplant eligible and those who are considered as nontransplant eligible. Transplant-eligible patients receive a primary proteasome inhibitor (PI)-based induction which is being combined with an immunomodulating agent and a CD38-directed monoclonal antibody followed by high-dose melphalan therapy and autologous stem cell transplantation with subsequent maintenance treatment with lenalidomide. Patients who are considered as nontransplant eligible receive upfront treatment preferentially with a continuous combination treatment either with a CD38-directed monoclonal antibody in combination with the immunomodulating agent lenalidomide or a lenalidomide-PI combination followed by lenalidomide maintenance. <b><i>Key Messages:</i></b> Primary goal of the initiated treatment is to induce a rapid and deep remission which ideally leads to an eradication of the residual plasma cell clone in sense of a minimal residual disease negativity. Achievement of long-term remission with limited toxicity despite continuous treatment strategies and maintenance or improvement of life-quality is key. Despite successful treatment options, specific difficult-to-treat subgroups, especially patients with high-risk myeloma remain with inferior prognosis and a clear unmet need for novel therapeutic strategies. Future concepts will evaluate cellular treatments and other innovative immunotherapies in first-line treatment in curative intention.

Sign in / Sign up

Export Citation Format

Share Document